Dabrafenib (Tafinlar)

Indications

  • Metastatic Melanoma with BRAF V600E Gene Mutation (see Melanoma, [[Melanoma]]): used in combination with the MEK inhibitor Trametinib (Mekinist) (see Trametinib, [[Trametinib]]), due to resistance to Dabrafenib which develops within 6-7 mo
    • FDA approved for this indication May 30, 2013

Pharmacology

  • BRAF (B-raf) Enzyme Inhibitor: BRAF plays a role in the regulation of cell growth

Administration

  • xxx

Adverse Effects

Other Adverse Effects

  • xxxx

References

  • xxx